Who
Anshul Thakral
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Fortrea Holdings; See Remarks., Ppd.
In numbers
- Trades disclosed
- 34
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $7.9M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 26 Nov 2019
- Last trade
- 6 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 7 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $1.0M55,882 at $18.17 | filing |
| 6 Aug 2026filed 7 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $1.0M55,975 at $18.06 | filing |
| 6 Aug 2026filed 7 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $1.0M55,882 at $18.17 | filing |
| 6 Aug 2026filed 7 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $1.0M55,975 at $18.06 | filing |
| 5 Aug 2026filed 6 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $941K49,452 at $19.03 | filing |
| 5 Aug 2026filed 6 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $972K50,417 at $19.28 | filing |
| 5 Aug 2026filed 6 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $941K49,452 at $19.03 | filing |
| 5 Aug 2026filed 6 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $972K50,417 at $19.28 | filing |
| 4 Aug 2026filed 6 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —416,666 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —416,666 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —416,666 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —416,666 at $0.00 | filing |
| 4 Aug 2025filed 4 Aug 2025 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —1,250,000 at $0.00 | filing |
| 8 Dec 2021filed 8 Dec 2021 | Ppdoption or derivative | SEC FORM 4 Code D | $6.7M207,836 at $32.45 | filing |
| 8 Dec 2021filed 8 Dec 2021 | Ppdoption or derivative | SEC FORM 4 Code A | —29,907 at $0.00 | filing |
| 8 Dec 2021filed 8 Dec 2021 | Ppdoption or derivative | SEC FORM 4 Code D | $8.3M224,119 at $36.91 | filing |
| 8 Dec 2021filed 8 Dec 2021 | Ppdoption or derivative | SEC FORM 4 Code A | —7,711 at $0.00 | filing |
| 8 Dec 2021filed 8 Dec 2021 | Ppdoption or derivative | SEC FORM 4 Code D | $1.3M38,560 at $32.51 | filing |
| 8 Dec 2021filed 8 Dec 2021 | Ppdoption or derivative | SEC FORM 4 Code A | —18,432 at $0.00 | filing |
| 8 Dec 2021filed 8 Dec 2021 | Ppdoption or derivative | SEC FORM 4 Code D | $1.8M69,123 at $25.80 | filing |
News
Critical Review: Champions Oncology (NASDAQ:CSBR) and Fortrea (NASDAQ:FTRE)FTRE · dailypolitical.com · 18 Oct 2026Reviewing MindWalk (NASDAQ:HYFT) & Fortrea (NASDAQ:FTRE)FTRE · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name Anshul Thakral; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.